Combination Ipatasertib and Atezolizumab to Prevent Recurrence in Triple Negative Breast Cancer

Age
18 years - 99 years
Gender
All
Location
1
Combination Ipatasertib and Atezolizumab to Prevent Recurrence in Triple Negative Breast Cancer

Brief description of study

The purpose of this study is to determine if a combination of two drugs, Ipatasertib and Atezolizumab, works as a treatment for residual cancer in breast or lymph nodes and have circulating tumor DNA in blood. Eligible subjects will be those with triple negative breast cancer.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Breast Cancer
  • Age: 18 years - 99 years
  • Gender: All


Updated on 04 Aug 2024. Study ID: 844085
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research